lornoxicam and Glucosephosphate-Dehydrogenase-Deficiency

lornoxicam has been researched along with Glucosephosphate-Dehydrogenase-Deficiency* in 1 studies

Trials

1 trial(s) available for lornoxicam and Glucosephosphate-Dehydrogenase-Deficiency

Article	Year
[Safety of lornoxicam in G-6-PDH deficiency]. Reumatismo, 2003, Volume: 55, Issue:1 To assess the safety of lornoxicam in subjects with G-6-PDH deficiency.. Open controlled 2-week in vivo study on lornoxicam 8 mg bid in subjects with G-6-PDH deficiency suffering from rheumatic diseases.. In 8 male patients with the Mediterranean form of G-6-PDH deficiency (mean age +/- SD, 54.3 years +/- 7.2) lornoxicam showed no influence on red blood cells (RBC) survival curve. The RBC half-life was the same before and after two weeks of treatment.. Lornoxicam caused no RBC damage and evidenced favourable safety in subjects with G-6-PDH deficiency, suffering from rheumatic diseases. Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Erythrocyte Aging; Glucosephosphate Dehydrogenase Deficiency; Humans; Male; Middle Aged; Piroxicam; Time Factors	2003

Article

Year

[Safety of lornoxicam in G-6-PDH deficiency].

Reumatismo, 2003, Volume: 55, Issue:1

To assess the safety of lornoxicam in subjects with G-6-PDH deficiency.. Open controlled 2-week in vivo study on lornoxicam 8 mg bid in subjects with G-6-PDH deficiency suffering from rheumatic diseases.. In 8 male patients with the Mediterranean form of G-6-PDH deficiency (mean age +/- SD, 54.3 years +/- 7.2) lornoxicam showed no influence on red blood cells (RBC) survival curve. The RBC half-life was the same before and after two weeks of treatment.. Lornoxicam caused no RBC damage and evidenced favourable safety in subjects with G-6-PDH deficiency, suffering from rheumatic diseases.

Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Erythrocyte Aging; Glucosephosphate Dehydrogenase Deficiency; Humans; Male; Middle Aged; Piroxicam; Time Factors

2003